Emerging Companies in the Taiwan Buprenorphine Market | Insights 2026

Emerging Companies in the Taiwan Buprenorphine Market

The Taiwan Buprenorphine Market is driven by eminent pharmaceutical brands providing opioid substitution therapies and innovative analgesics. Key players in the market include Indivior (Taiwan), Mundipharma Taiwan, TTY Biopharm Company Limited, and Lotus Pharmaceutical Co., Ltd.

Taiwan Buprenorphine Market Overview

According to 6Wresearch, the market for buprenorphine in Taiwan is currently undergoing steady expansion, due to the rising prevalence of opioid use disorders (OUD) and the growing need for effective chronic pain treatment solutions. Buprenorphine is a potent analgesic and partial opioid agonist, that is used for chronic pain management and opioid use disorder.

The market is boosted by the rising trend of using long-acting injectables and transdermal patches, which offer patients better compliance and effective solutions. In addition, various initiatives have been put in place by the Ministry of Health and Welfare and the National Health Insurance administration to ensure improved healthcare services and expanded access to medication-assisted treatments.

Competitive Landscape

The competitive landscape of the Taiwan buprenorphine industry includes several global and domestic manufacturers, especially in the specialized pain management and addiction medicine sectors. The dominant companies in the market sustain their prominent position with continued investment in R&D and strategic licensing agreements, which helps in the development of innovative drugs, thus catering to the growing need for effective buprenorphine drugs.

Below is a list of leading players operating in the Taiwan Buprenorphine Market

1. Indivior

Indivior is a global leader in addiction treatment, known for its Suboxone and Sublocade brands, which are critical for the management of opioid dependence.

2. Mundipharma Taiwan

Mundipharma is a pioneer in pain management, offering the Norspan patch, a transdermal buprenorphine delivery system widely used for chronic pain.

3. TTY Biopharm Company Limited

TTY Biopharm is a leading domestic player focusing on specialty drugs, including CNS and analgesics, through strong R&D and international licensing partnerships.

4. Lotus Pharmaceutical Co., Ltd.

Lotus is a fast-growing specialty pharma company that manufactures and commercializes complex generics and branded treatments for addiction.

5. Taiwan Biotech Co., Ltd.

Taiwan Biotech is an established domestic player that produces a variety of CNS medications and has a presence in the analgesic segment.

6. Orient Pharma Co., Ltd.

Orient Pharma specializes in the development of transdermal patches and oral controlled-release dosage forms, targeting the chronic pain management market.

7. Synmosa Biopharma Corp.

Synmosa focuses on specialized therapeutic areas including respiratory and CNS, providing high-quality pharmacological solutions.

8. Standard Chem & Pharm Co., Ltd.

Standard Chem is a major pharmaceutical manufacturer, producing a wide range of CNS and analgesic products through advanced manufacturing facilities.

9. U-Chu Pharmaceutical Co., Ltd.

U-Chu is recognized for its contribution to the domestic narcotic and analgesic market, maintaining a robust portfolio of opioid-based therapies.

10. Yung Shin Pharmaceutical Ind. Co., Ltd.

Yung Shin is one of Taiwan's largest pharmaceutical companies, providing extensive distribution and manufacturing of specialized therapies for chronic conditions.

Emerging Companies in the Taiwan Buprenorphine Market: FAQs